Phar­maEssen­tia takes Besre­mi rare blood can­cer mes­sage to con­sumers

Phar­maEssen­tia’s first prod­uct Besre­mi is the on­ly first-line treat­ment ap­proved for poly­cythemia ve­ra (PV). Now mar­ket­ed for more than a year, the drug­mak­er is ready …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER